Protein Subunit Vaccine Purification

2014 ◽  
pp. 181-216 ◽  
Author(s):  
Yan‐ping Yang ◽  
Tony D'Amore
Keyword(s):  
Subunit Vaccine ◽  
Protein Subunit

scholarly journals A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

2021 ◽  
Author(s):  
Neil C Dalvie ◽  
Lisa H Tostanoski ◽  
Sergio A Rodriguez-Aponte ◽  
Kawaljit Kaur ◽  
Sakshi Bajoria ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Cellular Response ◽  
Subunit Vaccine ◽  
Hepatitis B Surface Antigen ◽  
Low Cost ◽  
Humoral Response ◽  
High Volume ◽  
Developed Countries ◽  
Protein Subunit ◽  
Middle Income

Vaccines against SARS-CoV-2 have been distributed at massive scale in developed countries, and have been effective at preventing COVID-19. Access to vaccines is limited, however, in low- and middle-income countries (LMICs) due to insufficient supply, high costs, and cold storage requirements. New vaccines that can be produced in existing manufacturing facilities in LMICs, can be manufactured at low cost, and use widely available, proven, safe adjuvants like alum, would improve global immunity against SARS-CoV-2. One such protein subunit vaccine is produced by the Serum Institute of India Pvt. Ltd. and is currently in clinical testing. Two protein components, the SARS-CoV-2 receptor binding domain (RBD) and hepatitis B surface antigen virus-like particles (VLPs), are each produced in yeast, which would enable a low-cost, high-volume manufacturing process. Here, we describe the design and preclinical testing of the RBD-VLP vaccine in cynomolgus macaques. We observed titers of neutralizing antibodies (>104) above the range of protection for other licensed vaccines in non-human primates. Interestingly, addition of a second adjuvant (CpG1018) appeared to improve the cellular response while reducing the humoral response. We challenged animals with SARS-CoV-2, and observed a ~3.4 and ~2.9 log10 reduction in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, compared to sham controls. These results inform the design and formulation of current clinical COVID-19 vaccine candidates like the one described here, and future designs of RBD-based vaccines against variants of SARS-CoV-2 or other betacoronaviruses.

scholarly journals Protection of Hamsters Challenged with SARS-CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Followed by a Single Dose of Beta Variant Version of MVC-COV1901

2021 ◽  
Author(s):  
Tsun-Yung Kuo ◽  
Chia-En Lien ◽  
Yi-Jiun Lin ◽  
Meei-Yun Lin ◽  
Chung-Chin Wu ◽  
...  
Keyword(s):  
Subunit Vaccine ◽  
Virus Titer ◽  
Neutralizing Antibody ◽  
Protein S ◽  
Protein Subunit ◽  
Live Virus ◽  
The Third ◽  
Severity Of Disease ◽  
Potent Immune Response ◽  
Ancestral Strain

AbstractThe current fight against COVID-19 is compounded by the Variants of Concern (VoCs), which can diminish the effectiveness of vaccines, increase viral transmission and severity of disease. MVC-COV1901 is a protein subunit vaccine based on the prefusion SARS-CoV-2 spike protein (S-2P) adjuvanted with CpG 1018 and aluminum hydroxide. Here we used the Delta variant to challenge hamsters innoculated with S-2P based on the ancestral strain or the Beta variant in two-dose or three-dose regimens. Two doses of ancestral S-2P followed by the third dose of Beta variant S-2P was shown to induce the highest neutralizing antibody titer against live SARS-CoV-2 of the ancestral strain as well as all VoCs. All regimens of vaccination were able to protect hamsters from SARS-CoV-2 Delta variant challenge and reduce lung live virus titer. Three doses of vaccination significantly reduced lung viral RNA titer, regardless of using the ancestral or Beta variant S-2P as the third dose. Based on the immunogenicity and viral challenge data, two doses of ancestral S-2P followed by the third dose of Beta variant S-2P could induce broad and potent immune response against the variants.

scholarly journals Recombinant protein subunit vaccine reduces puerperal metritis incidence and modulates the genital tract microbiome

2020 ◽  
Vol 103 (8) ◽  
pp. 7364-7376 ◽  
Author(s):  
E.B.S. Meira ◽  
R.D. Ellington-Lawrence ◽  
J.C.C. Silva ◽  
C.H. Higgins ◽  
R. Linwood ◽  
...  
Keyword(s):  
Recombinant Protein ◽  
Genital Tract ◽  
Subunit Vaccine ◽  
Protein Subunit

scholarly journals Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine

2021 ◽  
Author(s):  
Jian Hang Lam ◽  
Amit Kumar Khan ◽  
Thomas Andrew Cornell ◽  
Regine Josefine Dress ◽  
Teck Wan Chia ◽  
...  
Keyword(s):  
Subunit Vaccine ◽  
Adaptive Immune Response ◽  
Cationic Lipid ◽  
Spike Protein ◽  
Protein Subunit ◽  
Vaccine Platform ◽  
Self Assembling ◽  
Generation Vaccine ◽  
Efficacious Vaccine ◽  
Th1 Cytokines

AbstractMultiple successful vaccines against SARS-CoV-2 are urgently needed to address the ongoing Covid-19 pandemic. In the present work, we describe a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG adjuvant. To enhance the immunogenicity of our formulation, both antigen and adjuvant were encapsulated with our proprietary artificial cell membrane (ACM) polymersome technology. Structurally, ACM polymersomes are self-assembling nanoscale vesicles made up of an amphiphilic block copolymer comprising of polybutadiene-b-polyethylene glycol and a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane. Functionally, ACM polymersomes serve as delivery vehicles that are efficiently taken up by dendritic cells, which are key initiators of the adaptive immune response. Two doses of our formulation elicit robust neutralizing titers in C57BL/6 mice that persist at least 40 days. Furthermore, we confirm the presence of memory CD4+ and CD8+ T cells that produce Th1 cytokines. This study is an important step towards the development of an efficacious vaccine in humans.

scholarly journals A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial

2020 ◽  
Author(s):  
Peter Richmond ◽  
Lara Hatchuel ◽  
Min Dong ◽  
Brenda Ma ◽  
Branda Hu ◽  
...  
Keyword(s):  
Older Adults ◽  
Immune Responses ◽  
Subunit Vaccine ◽  
Phase 1 ◽  
Intracellular Cytokine Staining ◽  
High Dose ◽  
Protein Subunit ◽  
Neutralising Antibodies ◽  
S Protein ◽  
Human Dose

ABSTRACTBackgroundAs part of the accelerated development of prophylactic vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) we report a first-in-human dose-finding and adjuvant justification study of SCB-2019, a novel protein subunit vaccine candidate composed of a stabilised trimeric form of the spike (S)-protein produced in CHO-cells, combined with two different adjuvants.MethodsThis phase 1 study was done in one centre in Western Australia in 151 healthy adult volunteers in two age groups (18–54 and 55–75 years), allocated to 15 groups (nine young and six older adults) to receive two doses, 21 days apart, of placebo, or 3 μg, 9 μg or 30 μg SCB-2019, alone or adjuvanted with AS03 or CpG/Alum. Reactogenicity was assessed for 7 days after each vaccination. Humoral responses were measured as SCB-2019 binding and ACE2-competitive binding IgG antibodies by ELISA, and as neutralising antibodies by wild-type SARS-CoV-2 microneutralisation assay; cellular responses to pooled S-protein peptides were measured by flow-cytometric intracellular cytokine staining.FindingsWe report on 148 participants with at least 4 weeks follow-up post dose 2. Three participants withdrew, two for personal reasons and one with an unrelated SAE (pituitary adenoma). Vaccination was well tolerated, with few Grade 3 solicited adverse events (AE). Most local AEs were mild injection site pain, which were more frequent with formulations containing AS03 than CpG/Alum or unadjuvanted SCB-2019. Systemic AEs, mostly transient headache, fatigue or myalgia, were more frequent in young adults than older adults after the first dose, but similar after second doses. Unadjuvanted SCB-2019 elicited minimal immune responses, but SCB-2019 with fixed doses of AS03 or CpG/Alum induced high titres and seroconversion rates of binding and neutralising antibodies in both young and older adults. Titres were higher than those observed in a panel of COVID-19 convalescent sera in all AS03 groups and high dose CpG/Alum groups. Both adjuvanted formulations elicited Th1-biased CD4+ T cell responses.InterpretationSCB-2019 trimeric protein formulated with AS03 or CpG/Alum adjuvants elicited robust humoral and cellular immune responses against SARS-CoV-2 with high viral neutralising activity. Both adjuvanted formulations were well tolerated and are suitable for further clinical development.Clinical trial registrationClinicalTrials.gov identifier NCT04405908.

scholarly journals Mycoplasma suis Alpha-Enolase Subunit Vaccine Induces an Immune Response in Experimental Animals

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1506
Author(s):  
Shujiang Xue ◽  
Kangseok Seo ◽  
Miaosen Yang ◽  
Chengdu Cui ◽  
Meng Yang ◽  
...  
Keyword(s):  
Subunit Vaccine ◽  
Vaccine Development ◽  
Protective Efficacy ◽  
Immunological Response ◽  
Proliferation Index ◽  
Protein Subunit ◽  
Cd8 Cells ◽  
Mycoplasma Suis ◽  
T Lymphocyte Proliferation ◽  
Ifn Γ

Recombinant protein technology has emerged as an excellent option for vaccine development. However, prior to our study, the immune induction ability of recombinant Mycoplasma suis alpha-enolase (rMseno) in animals remained unclear. The purpose of this study was to develop a rMseno protein subunit vaccine and to determine its ability to elicit an immunological response. To accomplish this, we cloned the gene into pET-15b, expressed it in BL21 cells, and purified it. Following the establishment of immunity, the immunogenicity and potential for protection of rMseno were evaluated in mice and piglets. The results demonstrate that anti-M. suis serum recognized the pure rMseno protein in both mice and piglets as evidenced by high levels of specific anti-rMseno antibodies, significantly increased levels of IFN-γ and IL-4 cytokines, and significantly increased T lymphocyte proliferation index. Piglets also had significantly increased levels of specific IgG1, IgG2a, CD4+, and CD8+ cells. The rMseno findings demonstrated a robust immunological response in mice and piglets, affording partial clinical protective efficacy in piglets.

Sign in / Sign up

Export Citation Format

Share Document